Newsletter Subject

Top Reasons to Buy Biotech Stocks Today

From

behindthemarkets.com

Email Address

newsletter@lg.behindthemarkets.com

Sent On

Mon, May 20, 2024 01:03 PM

Email Preheader Text

Major drug companies are on a shopping spree  here.  Prefer to view this content on our website?

Major drug companies are on a shopping spree [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, Biotech stocks offer some of the most explosive opportunities. That is, if you spot the right ones. For example, some of the hottest ideas can be found in weight loss drugs, cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing. --------------------------------------------------------------- Company: CRISPR Therapeutics (SYM: CRSP) Look at CRISPR Therapeutics (SYM: CRSP), for example. Not long ago, it received US FDA approval for its gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions. With that news, we watched CRISPR jump from about $40 to $70. --------------------------------------------------------------- Manward Press[This "AI parallel" stock is expected to grow 12,300% by 2030.]( Just $5,000 could turn into a $620,000 windfall. [Full Details Here]( --------------------------------------------------------------- Company: Eli Lilly (SYM: LLY) Or, look at Eli Lilly (SYM: LLY). Thanks to strong demand for obesity medication, the stock popped from about $580 to $760, and it’s still moving higher. Of course, there are many more. But you get the point. What makes biotech even hotter is that major drug companies are on a shopping spree. Over the next few years, drug giants could lose billions to patent expirations. According to EY analysts, the top 20 giants could lose about $180 billion in sales by the end of the decade. To stop some of the potential bloodshed, companies are building up their pipelines, bringing in fresh new drugs with multi-billion-dollar potential. For example, most recently, Johnson & Johnson said it would acquire Ambrx Biopharma for $2 billion. Pfizer acquired Seagen for $43 billion. --------------------------------------------------------------- InvestorPlace[Crypto Millionaire Names His Five Favorite Altcoins]( [bitcoin]( Crypto pioneer Charlie Shrem has an uncanny knack for spotting the biggest winners, like on Steem, Cindicator, and as much as the 200,000% he made on Bitcoin. Now, he says, there are five coins you must take a look at right away. [I want the details]( --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you own any biotech stocks? Do you have your eye on any opportunities we might have missed? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets](  [Unsubscribe]( Â

Marketing emails from behindthemarkets.com

View More
Sent On

08/12/2024

Sent On

07/12/2024

Sent On

07/12/2024

Sent On

07/12/2024

Sent On

06/12/2024

Sent On

06/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.